Home>>Signaling Pathways>> Others>>Malic enzyme inhibitor ME1

Malic enzyme inhibitor ME1 (Synonyms: ME1)

Catalog No.GC38506

Malic enzyme inhibitor ME1 (ME1; compound 1) is a potent inhibitor of Malic enzyme (ME1) with an IC50 of 0.15 μM.

Products are for research use only. Not for human use. We do not sell to patients.

Malic enzyme inhibitor ME1 Chemical Structure

Cas No.: 522649-59-8

Size Price Stock Qty
10mM (in 1mL DMSO)
$201.00
In stock
1mg
$88.00
In stock
5mg
$261.00
In stock
10mg
$449.00
In stock
25mg
$897.00
In stock
50mg
$1,530.00
In stock
100mg
$2,601.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Malic enzyme inhibitor ME1 (ME1; compound 1) is a potent inhibitor of Malic enzyme (ME1) with an IC50 of 0.15 μM[1][2].

Malic enzyme inhibitor ME1 (ME1; ME1*) (50 μM; 72 hours) shows a significant reduction in total cell numbers[2]. Malic enzyme inhibitor ME1 shows a significant reduction in cell viability/metabolic activity in MTS cell[2]. Malic enzyme inhibitor ME1 dose-dependently reduces the number of colonies formed by both HCT116 and HT29 cells[2]. Cell Viability Assay[2] Cell Line: HCT116 and HT29 cell line

[1]. Zhang YJ, et al. In silico design and synthesis of piperazine-1-pyrrolidine-2,5-dione scaffold-based novel malic enzyme inhibitors. Bioorg Med Chem Lett. 2006 Feb;16(3):525-8. Epub 2005 Nov 8. [2]. Fernandes L, et al. Malic Enzyme 1 (ME1) is pro-oncogenic in ApcMin/+ mice. Sci Rep. 2018 Sep 24;8(1):14268.

Reviews

Review for Malic enzyme inhibitor ME1

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Malic enzyme inhibitor ME1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.